The World Market for Cancer Diagnostics, 2024-2029
상품코드:1592137
리서치사:Kalorama Information
발행일:2024년 12월
페이지 정보:영문 295 Pages
라이선스 & 가격 (부가세 별도)
한글목차
정확한 진단, 치료법 선택, 치료 효과 모니터링, 암 재발 조기 발견에 필수적인 분자 및 단백질 바이오마커로 인해 암 진단의 상황은 진화하고 있습니다.
이 보고서는 세계 암 진단 시장을 조사하여 주요 카테고리에 초점을 맞추고, 이미징, 혈액학, 임상화학, 유세포 분석, 세포진, 기존 염색에 대해 다룹니다. 암 IVD 시장을 형성하는 주요 개발, 제품 출시, 규제 당국의 발표를 분석하고 2024년부터 2029년까지 시장 성장 예측을 제공합니다.
목차
제1장 주요 요약
제2장 소개, 배경, 개요
세계의 암 부담
암 개요
암세포 생화학
암 증식 원인이 치료의 실마리가 될 가능성
환경요인, DNA, RNA
세포 암 유전자
종양 억제 유전자
폭넓은 IVD 적용
조직학과 세포학
ISH(In Situ Hybridization)
면역측정
중합효소 연쇄 반응(PCR)
동반진단
약물 유전자 적합을 위한 예측 바이오마커 검사
DNA와 RNA 변이체
유전성 암 진단
널리 사용되고 있는 암 마커
암 치료 접근법
정밀 암 치료란 무엇인가?
제3장 시장 동향
정밀의료, 동반진단, 관련 용도의 성장
약물 진단 검사
액체 생검에 기반한 비침습성 암 분자진단
순환종양세포(CTC) 검사
샘플 수집 제품
엑소좀 배열 해석
차세대 시퀀싱 검사
전장 유전체 배열 해석
엑솜 시퀀싱
RNA 시퀀싱
규제의 영향
기업
고급 분석 솔루션
조직학 자동화
인공지능
질량 분석
규제와 상환 동향
보험 상환의 진보와 과제
차세대 시퀀싱 커버리지
동반진단의 규제 개발
임상 검사(LDT)
식품의약품국
지침 98/79/EC
캐나다 보건부의 변경과 예상되는 조치
국제적 성장 기회
제4장 시장 매출과 예측
제5장 경쟁 분석
제6장 기업 개요
Abbott Diagnostics
Agendia BV
Agilent Technologies
Asuragen(Bio-Techne)
Beckman Coulter(Danaher)
Becton, Dickinson and Company(BD)
Bio-Rad Laboratories
Biocartis
Biodesix
Biotheranostics, Inc.(Hologic)
Danaher Corp.
Exact Sciences
Exosome Diagnostics(Bio-Techne)
Hologic
Illumina
Leica Biosystems(Danaher)
Menarini-Silicon Biosystems
Qiagen
Roche
Sysmex Inostics
Thermo Fisher Scientific
ksm
영문 목차
영문목차
The landscape of cancer diagnostics is evolving with molecular and protein biomarkers indispensable for accurate diagnosis, therapy selection, monitoring treatment response, and early detection of cancer recurrence. Kalorama Information's "The World Market for Cancer Diagnostics, 2024-2029" delivers an authoritative and comprehensive analysis of the global cancer in vitro diagnostics (IVD) market, including industry-defining trends, market sizing, and growth opportunities.
This report offers an in-depth review of the cancer IVD market, including expert insights into significant segment markets:
While focusing on these pivotal categories, the report provides limited coverage of imaging, hematology, clinical chemistry, flow cytometry, Pap smears, and traditional stains. Key developments, product launches, and regulatory announcements that shape the cancer IVD market are analyzed, along with forecasts for market growth from 2024 to 2029.
Key Highlights
Shift to Biofluid-Based Diagnostics: Although tissue-based diagnostics dominate the current market, there is growing momentum toward biofluid-based tests (e.g., blood, urine) for cancer detection and monitoring.
Market Dynamics: The forecasted growth reflects anticipated product innovations, cancer epidemiology trends, and demographic shifts, with revenue estimates based on factory-level sales to end users.
Comprehensive Insights: The report incorporates global cancer statistics, technological advancements, and competitive trends to provide a nuanced view of the market's evolution.
Report Structure
1. Executive Summary - A concise overview of key findings and market scope.
2. Introduction and Overview - Background and terminology for context.
3. Market Trends - Emerging trends shaping the cancer diagnostics industry.
4. Market Revenues and Forecasts - Detailed revenue projections by segment through 2029.
5. Competitive Analysis - Analysis of key market players and competitive developments.
6. Corporate Profiles - Profiles of leading companies in the cancer diagnostics space.
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Market Overview and Analysis
Figure 1-1: Global Cancer IVD Market Size and Forecast, 2024-2029 ($ million)
Chapter 2: Introduction, Background, and Overview
Global Cancer Burden
Figure 2-1: Incidence of Cancer, by Type, 2020 (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid)
Figure 2-2: Global Distribution of Cancer Incidence, Estimated Number of New Cases, by Type, 2020 (%) (Breast, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Thyroid, Other Cancers)
Introduction to Cancer
Biochemistry of Cancer Cells
Causes of Cancer Growth May Shed Light on Treatment
Environmental Factors, DNA, RNA
Table 2-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
Large Range of IVDs Applied
Histology and Cytology
In Situ Hybridization (ISH)
Immunoassays
Polymerase Chain Reaction (PCR)
Companion Diagnostics
Table 2-2: FDA Approved or Cleared Companion Diagnostic (CDx) Tests and Corresponding Therapies, Oncology
Table 2-3: Selected Major Biomarkers in Oncology Personalized Medicine Tests
Predictive Biomarker Tests for Drug-Gene Match
DNA and RNA Variants
Table 2-4: Human Genome and Cancer Gene Identification
Table 2-5: Relevant DNA/RNA Variants for Top Six Cancer Types (Breast, Colon, Gastric, Liver/Biliary, Lung, Prostate)
Table 2-6: Relevant DNA/RNA Variants for Top Six Cancer Types (excl. top six) (Brain, Cervical, Esophagus, Leukemia, Lymphoma, Melanoma, Ovarian, Pancreatic, Sarcoma, Thyroid)
Diagnostics in Hereditary Cancer Diagnosis
Table 2-7: Select Innovations in Molecular Cancer Risk Detection and Prevention
Table 2-8: Selected Companies Offering LDTs for Hereditary Risk of Cancer
Cancer Markers in Widespread Usage
Cancer Treatment Approaches
Table 2-9: Characteristics of Cancer Treatment Approaches (Chemotherapy, Hormone Therapy, Precision Therapy)
What is Precision Cancer Therapy?
Table 2-10: Industry Recognized Terms for Companion Diagnostics and Personalized Medicine
Chapter 3: Market Trends
Growth in Precision Medicine, Companion Diagnostics, Related Applications
Table 3-1: Selected Molecular Companion and Complementary Assays for Cancer
Table 3-2: Selected Pharmacogenomic Biomarkers and Drugs' Labeling, FDA
Table 3-3: Selected FDA Cleared/Approved Companion Diagnostic Tests and Therapeutic Application
Pharmacodiagnostic Tests
Table 3-4: Selected Liquid Biopsy Innovations
Liquid Biopsy-based Non-Invasive Cancer Molecular Diagnostics
Table 3-8: Selected Mass Spectrometry-Based Oncology Tests
Regulatory and Reimbursement Trends
Reimbursement Breakthroughs and Challenges
Next Generation Sequencing Coverage
Companion Diagnostics Seeing Development in Regulations
Table 3-9: FDA Approved Companion Diagnostics Labeled for Identifying Patients with NSCLC whose Tumors have EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations and the Associated Therapeutic Products
Figure 3-1: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ million)
Figure 3-2: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics (%)
